80069664 - Johns Hopkins Wilmer Eye Institute's 38th Annual Current Concepts in Ophthalmology

Thursday, December 4, 2025, 7:00 AM - Friday, December 5, 2025, 5:00 PM, Johns Hopkins University School of Medicine, Turner Bldg., Baltimore, MD


This comprehensive two day course is designed to equip ophthalmologists with timely updates on advances in clinical research, diagnostic imaging, and both medical and surgical therapies across the full spectrum of eye care. Expert faculty will review emerging evidence and evolving practice patterns in areas such as age related macular degeneration, diabetic retinopathy, glaucoma, cataract surgery, corneal disease, pediatric ophthalmology, and oculoplastic disorders. Through lectures, panels, and interactive discussions, participants will gain the knowledge and confidence to integrate these advances into their own practice, with the ultimate goal of improving patient outcomes and quality of life.

1. Summarize the latest developments for the management of anterior and posterior segment problems.
2. Evaluate emerging literature on the efficacy, safety, and costeffectiveness of femtosecondassisted laser cataract surgery.
3. Examine external legislative and internal practice issues impacting the field of ophthalmology.
4. Assess the perioperative use of antibiotics and antiinflammatory agents in patients undergoing eye surgery.
5. Integrate prescribed medical and surgical treatment options into everyday practice.

Canopy by Hilton Baltimore Harbor Point
1215 Wills Street
Baltimore, MD 21231
Hotel Phone: 443-960-8673
Hotel Rate: $213.18
Hotel Link: https://www.hilton.com/en/attend-my-event/bwihppy-927-5b83cd66-b710-4d9c-aff3-b9e3abe619f9/
Hotel Registration Cut Off Date: 11/3/2025

Mitigation of Relevant Financial Relationships

Johns Hopkins University adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.